Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

10.10   Exclusive License Agreement, dated February 15, 2006, between Glycosan BioSystems, Inc. and the University of Utah Research Foundation, as amended (14)
     
10.11   Form of Employee Incentive Stock Option Agreement (15)
     
10.12   Form of Non-employee Director Stock Option Agreement (15)
     
10.13   Option Agreement, dated March 4, 2014, between BioTime and certain investors (16)
     
10.14   Employment Agreement, dated December 29, 2014, between BioTime, Inc. Aditya Mohanty (17)
     
10.15   2012 Equity Incentive Plan, as amended (18)
     
10.16   Research & Development Agreement, dated September 29, 2015, between OrthoCyte Corporation and Heraeus Medical GmbH (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (19)
     
10.17   License Agreement, dated September 29, 2015, between OrthoCyte Corporation and Heraeus Medical GmbH (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (19)
     
10.18   Employment Agreement, dated November 16, 2015, between BioTime, Inc. and Russell Skibsted (20)
     
10.19   Amendment of Employment Agreement, dated November 24, 2015, between BioTime, Inc. and Michael D. West (21)
     
10.20   Amendment of Employment Agreement, dated November 24, 2015, between BioTime, Inc. and Aditya Mohanty (21)
     
10.21   Lease, dated December 10, 2015, between BioTime, Inc. and BSREP Marina Village Owner LLC (22)
     
10.22   Cross-License Agreement, dated February 16, 2016, among Asterias Biotherapeutics, Inc., BioTime, Inc., and ES Cell International Pte. Ltd. (23)
     
10.23   Cell Cure Neurosciences Ltd. Share Option Plan (24)
     
10.24   Form of Cell Cure Neurosciences Ltd. Share Option Plan Option Agreement (24)
     
10.25   Controlled Equity OfferingSM Sales Agreement, dated as of April 6, 2017 between BioTime, Inc., and Cantor Fitzgerald & Co. (25)
     
10.26   Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure Neurosciences, Ltd. and Hadasit Medical Research Services and Development Ltd. (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (26)
     
10.27   Debt and Note Purchase Agreement, dated June 16, 2017, as amended June 29, 2017, between BioTime, Inc. and HBL-Hadasit Bio-Holdings Ltd. (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (26)
     
10.28   Share Purchase and Transfer Agreement, dated June 16, 2017, by and among BioTime, Inc. and HBL-Hadasit Bio-Holdings Ltd. and Cell Cure Neurosciences Ltd. (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) (26)
     
10.29   2017 Amendment to 2012 Equity Incentive Plan (27)
     
10.30   Asset Contribution and Separation Agreement, dated August 17, 2017, between BioTime, Inc. and AgeX Therapeutics, Inc. (28)

 

 4 

© Copyright BioTime, Inc.